Drugs / CF33-CD19
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06063317 | Oct 2023 → Feb 2026 | cancer | Imugene Limited | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-11-10 | Celularity Incorporated | Results Imugene’s onCARlytics combination with Celularity’s placental-derived off-the-shelf allogeneic CYCART-19 T cells preclinical data presented at SITC Annual Meeting celularity.com ↗
CYCART-19 treatment 7 days post onCARlytics infection showed significant tumor regression compared to onCARlytics or T cells alone in a mouse xenograft model of triple-negative breast cancer. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-11-10 | Celularity Incorporated | Imugene’s onCARlytics combination with Celularity’s placental-derived off-the-shelf allogeneic CYCART-19 T cells preclinical data presented at SITC Annual Meeting celularity.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CF33-CD19 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06063317 ↗ |
| Known as | onCARlytics | “A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab” NCT06063317 ↗ |
| Route | Other | “administered intratumorally” NCT06063317 ↗ |